Published in Hepatitis Weekly, December 25th, 2006
"Thirteen percent (n=88) of the comparator lamivudine (LVD)-treated patients experienced a virologic rebound (>or=1 log increase from nadir by PCR) in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-12-25)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.